Farnum Rhonda sold 13,314 Theravance Biopharma shares in three transactions at $17.03 per share, leaving 213,476 shares after the trades. For investors, the disclosed sale equals about 5.9% of Rhonda’s prior holding, while the transaction record identifies all three disposals with code S.
Key Highlights
- Farnum Rhonda’s three transactions covered 13,314 Theravance Biopharma shares.
- Each transaction was priced at $17.03 per share on 15 September 2026.
- Rhonda held 213,476 shares after the transactions, equivalent to about 5.9% of the prior holding.
Three Transactions at $17.03 Per Share
Theravance Biopharma, Inc. is a biotechnology company. The transactions were dated 15 September 2026 and covered the same per-share price in each entry. The reported pricing range was $17.03 to $17.03 per share, with the aggregate activity spanning 13,314 shares. Theravance identified Farnum Rhonda with the title SVP, COMM & MEDICAL AFFAIRS in connection with the transactions. Following the three entries, Rhonda’s reported ownership stood at 213,476 shares. The transaction record stated that the sale represented about 5.9% of Rhonda’s prior share holding.
FAQs
Q: How many Theravance Biopharma shares did Farnum Rhonda sell?
A: Farnum Rhonda sold 13,314 shares of Theravance Biopharma across three transactions. The combined total covers all three entries dated 15 September 2026.
Q: At what price did Farnum Rhonda sell TBPH shares?
A: Each reported share sale was priced at $17.03. The stated transaction range was $17.03 to $17.03 per share.
Q: How many Theravance Biopharma shares did Rhonda own after the sale?
A: Rhonda’s reported ownership after the transactions was 213,476 shares. The sale represented about 5.9% of the prior share holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.